Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 8Completed 6Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 33OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

HER2-expressing Advanced Solid Tumors 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × pyrotinib × Clear all
NCT06015048 2024-08-05

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
364 enrolled
Other solid neoplasm

HER2-expressing Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡